BIOMARKER:

EGFR exon 18 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

EGFR exon 18 mutation	Non Small Cell Lung Cancer	EGFR exon 18 mutation	Non Small Cell Lung Cancer	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2	afatinib Sensitive: C2 – Inclusion Criteria afatinib Sensitive : C2
EGFR exon 18 mutation	Non Small Cell Lung Cancer	EGFR exon 18 mutation	Non Small Cell Lung Cancer	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2	erlotinib Sensitive: C2 – Inclusion Criteria erlotinib Sensitive : C2
EGFR exon 18 mutation	Non Small Cell Lung Cancer	EGFR exon 18 mutation	Non Small Cell Lung Cancer	bevacizumab + erlotinib Sensitive: C3 – Early Trials bevacizumab + erlotinib Sensitive : C3	bevacizumab + erlotinib Sensitive: C3 – Early Trials bevacizumab + erlotinib Sensitive : C3
EGFR exon 18 mutation	Non Small Cell Lung Cancer	EGFR exon 18 mutation	Non Small Cell Lung Cancer	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3	neratinib Sensitive: C3 – Early Trials neratinib Sensitive : C3
EGFR exon 18 mutation	Non Small Cell Lung Cancer	EGFR exon 18 mutation	Non Small Cell Lung Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
EGFR exon 18 mutation	Non Small Cell Lung Cancer	EGFR exon 18 mutation	Non Small Cell Lung Cancer	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3	FCN-411 Sensitive: C3 – Early Trials FCN-411 Sensitive : C3
EGFR exon 18 mutation	Lung Adenocarcinoma	EGFR exon 18 mutation	Lung Adenocarcinoma	bevacizumab + afatinib Sensitive: C4 – Case Studies bevacizumab + afatinib Sensitive : C4	bevacizumab + afatinib Sensitive: C4 – Case Studies bevacizumab + afatinib Sensitive : C4